FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer
“Receiving Fast Track designation from the FDA reinforces the promise of CD24 as a next-generation immuno-oncology target and highlights the potential of PHST001 to address a critical unmet need in the treatment of ovarian cancer,” said Raphaël Rousseau, M.D., Ph.D., Chief Medical Officer, Pheast Therapeutics. “We are committed to advancing PHST001 through the clinic and accelerating its development for cancer patients in urgent need of more effective treatments.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.